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T he prognosis of systemic lupus erythematosus (SLE) has been dramatically improved by the pro-
gression of immunosuppressive therapy [1].  The initia-
tion of glucocorticoids (GCs) and hydroxychloroquine 
(HCQ) in the 1950s was the first innovation in the 
management of SLE [2 , 3].  Subsequently,  in the 1970s,  
combination treatment with GCs and several immuno-
suppressants,  including azathioprine and cyclophos-
phamide,  was started [4-7].  In the 1990s,  concomitant 
use of mycophenolate mofetil (MMF) and/or a calci-
neurin inhibitor with GCs emerged as new treatment 
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Chronic damage accumulation affects not only mortality but also quality of life in patients with systemic lupus 
erythematosus (SLE).  Risk factors for chronic damage were explored in SLE through different onset eras.  Two 
hundred forty-five patients at Okayama University Hospital and Showa University Hospital were divided into 
three groups based on the onset era: a past-onset group (onset before 1995; n = 83),  middle-onset group 
(1996-2009; n = 88),  and recent-onset group (after 2010; n = 74).  The mean Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score as an index of chronic 
damage was 1.93,  1.24,  and 0.53 in the past-,  middle-,  and recent-onset groups,  respectively.  In the past- 
onset group,  the total SDI score was significantly associated with glucocorticoid monotherapy by linear regres-
sion analysis (β-coefficient [β] = 0.63; 95% confidence interval [CI],  0.21-1.05) and C-reactive protein levels 
(β = 0.67; 95% CI,  0.27-1.07).  In the middle-onset group,  the total SDI score was significantly associated with 
the SLE Disease Activity Index at registration (β = 0.09; 95% CI,  0.03-0.12).  Reducing the accumulation of 
chronic damage in SLE patients might be possible with the concomitant use of immunosuppressants and tight 
control of disease activity.
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options [8-11].  More recently,  several biological agents,  
including belimumab,  known as a B-cell activating fac-
tor inhibitor,  have become available for the treatment of 
SLE.
Followed by the improvement of prognosis,  the 
accumulation of chronic damage has become a major 
concern in the clinical course of patients with SLE 
[12 , 13].  The accumulation of chronic damage is asso-
ciated not only with mortality,  but also with a reduced 
quality of life [14-17].  During a mean 5-year disease 
duration,  disease activity was reported as the main risk 
factor for chronic damage [18 , 19].  In studies that 
included patients with a mean 10-year disease duration,  
the accumulation of chronic damage was related to dis-
ease activity,  demographic factors,  treatment status,  
and complications [20-22].  However,  only older age 
and use of GCs were risk factors in the studies that 
included patients with a mean disease duration of over 
10 years [23-25].  The factors related to chronic damage 
have been speculated to change with the onset era due 
to the staggered emergence of different treatment 
options.
In the present study,  we explored the risk factors for 
chronic damage in patients with SLE across different 
onset eras.
Methods and Patients
Study design and patients. This study had a 
cross-sectional design,  using enrollment data from our 
registry of patients with SLE (Lupus Registry of the 
Nationwide Institution [LUNA]).  We commenced reg-
istration for the LUNA registry in February 2016.  All 
patients were older than 20 years,  and they fulfilled ≥ 4 
of the American College of Rheumatology criteria for 
the classification of SLE [26].  For the present study,  we 
analyzed the LUNA data for patients registered at 
Okayama University and Showa University between 
February 2016 and September 2016.
The data for each patient in the LUNA registry 
included demographic information,  date of onset,  
underlying comorbidity,  smoking and drinking habits,  
past medical history,  reproductive history,  and blood 
pressure.  Laboratory data at registration were also 
included,  and consisted of complete blood count,  bio-
chemical examination,  urinalysis,  complement levels,  
anti-double-stranded DNA antibody titer,  and 
anti-phospholipid antibody.  Disease activity and dam-
age were evaluated using the SLE Disease Activity Index 
(SLEDAI) and the Systemic Lupus International Col-
laborating Clinics /American College of Rheumatology 
Damage Index (SDI),  respectively [27, 28].  Informa-
tion about current and previous treatment,  such as 
prednisolone dosage,  concomitant use of immunosup-
pressants,  and treatments for comorbidity (e.g.,  diabe-
tes mellitus,  dyslipidemia,  hypertension,  osteoporosis,  
and infections),  was also collected.  All data for LUNA 
were collected from electronic medical records and 
patient-reported information.
This study was conducted in accordance with the 
Declaration of Helsinki and the ethical guidelines for 
epidemiological research in Japan.  This study was 
approved by the Ethics Committee of Okayama 
University Hospital and Graduate School of Medicine,  
Dentistry,  and Pharmaceutical Sciences (Ken1807-002).  
Patient consents for participation in this study were 
obtained by an opt-out consent form.
Statistical analysis. We initially described the 
characteristics of all enrolled patients,  and then 
explored the factors related to the total SDI score.  The 
patients were divided into three groups based on the 
onset era: a past-,  middle- and recent-onset group with 
onset before 1995,  between 1996 and 2009,  and after 
2010,  respectively.  We explored the factors related to 
total SDI score using uni- and multivariate linear 
regression analyses in each group.  Candidate factors for 
multivariate analyses were selected based on the univar-
iate analysis results.
Clinical characteristics were presented as the mean 
±standard deviation (SD).  Continuous variables were 
compared using the Mann–Whitney U test,  whereas 
categorical variables were compared between the 2 
groups using the Fisher’s exact probability test.  A 
p-value of < 0.05 was considered significant.  When 
comparing three categories,  statistical significance was 
determined by using the Bonferroni correction to adjust 
for multiple testing (p < 0.05/3).  All statistical analyses 
were performed using the JMP 11.2.0 software package 
(SAS Institute Inc.,  Cary,  NC,  USA).
Results
Baseline characteristics and treatment status.
Two hundred and forty-five patients with SLE were 
included in the present study.  The mean (±SD) disease 
onset age of the enrolled patients was 28 (±14) years;  
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222 patients (91%) were female.  The mean disease 
duration was 13 (±10) years.  The mean (±SD) SLEDAI 
and total SDI score at the registration were 5.0 (±5.1) 
and 1.3 (±1.7),  respectively.  Treatments at the registra-
tion were as follows: GC monotherapy in 78 (32%) 
patients,  immunosuppressant monotherapy in 4 (2%),  
and concomitant immunosuppressants with GCs in 144 
(58%).  Nineteen (8%) patients had no immunosup-
pressive treatments.
On univariate analysis,  the total SDI score was sig-
nificantly associated with sex,  age at disease onset,  dis-
ease duration,  SLEDAI at registration,  GC monother-
apy,  C3,  C4,  CH50,  white blood cell (WBC) count,  
C-reactive protein (CRP),  and glycated hemoglobin 
(HbA1c).  Multivariate analysis using the above vari-
ables (WBC count,  C3,  C4,  and CH50 were excluded 
because SLEDAI at registration included those vari-
ables) showed that age at disease onset (β-coefficient 
[β]= 0.083; 95% confidence interval [CI],  0.02 to 0.05),  
disease duration (β = 0.08; 95% CI,  0.05 to 0.11),  
SLEDAI at registration (β = 0.08; 95% CI,  0.03 to 0.12),  
and CRP (β = 0.47; 95% CI,  0.21 to 0.73) were the fac-
tors significantly related to the total SDI score (Table 1).
Comparison of patient characteristics across differ-
ent onset eras. Patient characteristics across the three 
different onset eras are shown in Table 2.  Patients in the 
past-onset group had a significantly younger age onset 
than those in the other 2 groups (the past-onset vs the 
middle-onset group,  p = 0.0031; and the past-onset vs 
the recent-onset group,  p = 0.0005).  The patients in the 
recent-onset group were taller than those in the past- 
onset group (p = 0.016).  With regard to the laboratory 
data,  CH50 levels in the past-onset group were signifi-
cantly higher than those in the other 2 groups (the 
past-onset vs the middle-onset group,  p = 0.0077; the 
past-onset vs the recent-onset group,  p = 0.0049).  The 
middle-onset group had lower C4 levels than the 
past-onset group (p = 0.011).  The WBC count of the 
recent-onset group was significantly lower than that of 
the past-onset group (p = 0.0016).
Comparisons of total SDI score and each compo-
nent score across the three different onset eras are 
shown in Fig. 1.  The mean (±SD) total SDI scores were 
1.94 (2.00),  1.24 (1.75),  and 0.53 (0.81) in the past-,  
middle-,  and recent-onset groups,  respectively.  
Significant differences in total SDI score were found 
across the 3 groups (the past-onset vs the middle-onset 
group,  p = 0.0081; the past-onset vs the recent-onset 
group,  p < 0.0001; the middle-onset vs the recent-onset 
group,  p = 0.0092).  The peripheral vascular score of the 
recent-onset group was significantly lower than that of 
the past- and middle-onset groups (the past-onset vs the 
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????? ?　 Linear regression analysis of total SDI
Univariate Multivariate
Coefficient 95% CI p-value Coefficient 95% CI p-value
Sex 0.41 0.04,  0.78 0.03 0.30 -0.09,  0.69 0.13
Age of disease onset 0.03 0.01,  0.04 0.0003 0.03 0.02,  0.05 0.0002
Disease duration 0.06 0.04,  0.08 <0.0001 0.08 0.05,  0.11 <0.0001
Weight 0.006 -0.01,  0.03 0.55
BMI 0.03 -0.02,  0.09 0.22
SLEDAI 0.07 0.02,  0.11 0.002 0.08 0.03,  0.12 0.0009
Dosage of PSL -0.003 -0.04,  0.04 0.88
GC monotherapy 0.36 0.14,  0.59 0.002 0.18 -0.11,  0.46 0.23
WBC count 0.0001 0.00003,  0.0002 0.009
Lymphocyte count -0.0003 -0.02,  0.02 0.97
Plt -0.011 -0.04,  0.02 0.45
CRP 0.64 0.35,  0.92 <0.0001 0.47 0.21,  0.73 0.0005
C3 0.009 0.002,  0.02 0.008
C4 0.07 0.04,  0.09 <0.0001
CH50 0.03 0.01,  0.06 0.003
Anti-ds-DNA antibody -0.002 -0.008,  0.004 0.52
HbA1c 0.86 0.41,  1.32 0.0002 0.40 -0.04,  0.83 0.07
SDI,  Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; CI,  confidence interval; BMI,  
body mass index; SLEDAI,  Systemic Lupus Erythematosus Disease Activity Index; PSL,  prednisolone; GC,  glucocorticoid; WBC,  white 
blood cell; Plt,  platelet; CRP,  C-reactive protein; ds-DNA,  double strand-deoxyribonucleic acid; HbA1c,  glycated hemoglobin.
recent-onset group,  p = 0.0021; the middle-onset vs the 
recent-onset group,  p = 0.014),  while the ocular,  renal,  
cardiovascular,  and musculoskeletal scores of the 
past-onset group were significantly higher than those of 
the recent-onset group (p < 0.0001,  p = 0.0043,  
p = 0.0088,  and p = 0.0085,  respectively).
Risk factors for chronic damage in each onset era.
Subsequently,  we explored the factors for the total SDI 
score using uni- and multivariate linear regression anal-
ysis in each onset era.
Table 3 shows the linear regression analysis results in 
the past-onset group.  On univariate analysis,  the total 
SDI score was significantly associated with the propor-
tion of GC monotherapy,  CRP level,  and C4 level.  
Multivariate analysis using these three variables 
revealed that GC monotherapy (β = 0.63; 95% CI,  0.21 
to 1.05) and CRP level (β = 0.67; 95% CI,  0.27 to 1.07) 
were the independent risk factors for total SDI score.
The linear regression analysis results of the mid-
dle-onset group are shown in Table 4.  Univariate anal-
ysis revealed that total SDI score had significant correla-
tions with sex; age at disease onset; SLEDAI at 
registration; HbA1c; C3; and C4 levels.  On multi-
variate analysis using these variables (C3 and C4 were 
not included because SLEDAI included them),  SLEDAI 
at registration (β = 0.09; 95% CI,  0.03 to 0.12) and age 
at disease onset (β = 0.05; 95% CI,  0.02 to 0.08) were 
independently related with total SDI score in the mid-
dle-onset group.
In the recent-onset group,  total SDI score was asso-
ciated with sex,  age at disease onset,  and C3 level on 
univariate analysis (Table 5).  On multivariate analysis,  
age at disease onset was the only independent factor 
related to the total SDI score (β = 0.02; 95% CI,  0.01 to 
0.04).
Discussion
In the present study,  we focused on the factors 
related to chronic damage in patients with SLE across 
different onset eras.  Because clinical practice has 
changed dramatically over the past 20 years,  evaluating 
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????? ?　 Patient characteristics at enrollment
Past-onset group:  
Onset before 1995 
(n=83)
Middle-onset group:  
Onset between 1996 and 2009 
(n=88)
Recent-onset group:  
Onset after 2010 
(n=74)
Female,  n (%) 77 (93) 79 (90) 66 (89)
SLEDAI 4.3±4.7 6.0±6.1 4.5±4.1
Height,  cm† 155±7 158±7 158±6
Weight,  kg 53±10 55±12 55±12
BMI 21.7±4.1 21.8±3.7 22.0±4.4
Age of disease onset,  years＊,† 29±14 35±16 36±15
Duration of disease,  years＊,＃,† 24.5±6.8 10.9±2.6 3.4±1.7
Dosage of PSL,  mg/day 5.8±3.7 7.0±5.1 7.3±8.1
GC monotherapy,  n (%) 35 (42) 23 (26) 20 (27)
???????????????
Serum C3,  mg/dL 86.3±21.3 82.1±21.8 85.8±49.7
Serum C4,  mg/dL＊ 17.9±7.9 15.1±6.9 15.4±8.4
CH50,  U/mL＊,† 37.2±9.5 33.5±9.5 32.3±10.0
Anti-ds-DNA antibody,  IU/mL 17.6±34.2 23.4±45.2 20.3±28.3
WBC count,  /μL† 6,304±2,257 5,693±2,003 5,232±2,090
Lymphocyte count,  /μL 1,152±619 1,107±652 1,190±709
Hb,  g/dL 12.3±1.5 12.5±1.4 12.3±1.4
Plt,  ×104/μL 22.5±8.0 23.7±8.1 23.8±7.1
CRP,  mg/dL 0.37±1.07 0.29±0.50 0.31±0.80
HbA1c,  % 5.8±0.8 5.8±0.5 5.6±0.4
Comparisons between the past-onset,  middle-onset,  and recent-onset groups were made using the Mann‒Whitney U test or Fisherʼs exact 
probability test.  Statistical significance was determined by using the Bonferroni correction (p<0.05/3): ＊Past-onset vs middle-onset group;
＃Middle-onset vs recent-onset group; †Past-onset vs recent-onset group.
SLEDAI,  systemic lupus erythematosus disease activity index; BMI,  body mass index; PSL,  prednisolone; GC,  glucocorticoid; ds-DNA,  
double strand-deoxyribonucleic acid; WBC,  white blood cell; Hb,  hemoglobin; Plt,  platelet; CRP,  C-reactive protein; HbA1c,  glycated 
hemoglobin.
the risk factors for chronic damage was difficult in a 
single population that included patients with both 
recent and past onset of disease.  Evaluation in each 
onset era provided different factors related to the accu-
mulation of damage as represented by the SDI score.
Patients in the past-onset group had a significantly 
younger disease onset,  were treated with GC mono-
therapy more frequently,  and tended to be treated with 
a lower dosage of GC than those in the middle- and 
recent-onset groups.  The components of SDI also dif-
fered significantly among groups.  Previous reports in 
patients with a mean disease duration of over 10 years 
identified only older age at onset and GC use as risk 
factors for the accumulation of chronic damage [23-25].  
However,  it is necessary to evaluate the risk factors for 
the accumulation of chronic damage separately by dis-
ease onset era,  because patient characteristics and treat-
ment status,  such as age at disease onset and immuno-
suppressant usage,  vary among eras.
In the past-onset group,  GC monotherapy and CRP 
level were significantly associated with total SDI score.  
GC use is a strong,  well-known risk factor for the accu-
mulation of chronic damage,  and the CRP level is asso-
ciated with disease activity and organ damage in SLE 
patients [25 , 29 , 30].  Although we could not evaluate 
the cumulative GC dose,  GC monotherapy in the pres-
ent study might reflect a portion of the cumulative GC 
dose,  because GC monotherapy requires a greater GC 
dose for disease control.  Considering that the dosage of 
GC was lower in the past-onset group,  the CRP levels in 
this study may reflect atherosclerosis caused by long-
term GC monotherapy rather than current disease 
activity [31-35].  The higher WBC counts and CH50 
levels in the past-onset group also suggest that patients 
in the past-onset group exhibited lower disease activity 
than the other groups.  In the present study,  patients in 
the recent-onset group received GC monotherapy less 
frequently,  so the rate of GC-related damage accumu-
lation may decline in the future.
In the middle-onset group,  the total SDI score was 
significantly related to current SLEDAI.  Previous 
reports also revealed that disease activity itself is a risk 
factor for SDI score accumulation [18 , 19].  Therefore,  
tight maintenance of remission may be important in the 
middle-onset group.  In contrast,  total SDI score in the 
recent-onset group was not associated with current dis-
ease activity and was only related to age at disease onset.  
Because the increase rate of the SDI score is reportedly 
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A Ocular†
Neuropsychiatric
Renal†
Pulmonary
Cardiovascular†
Peripheral vascular♯,†
Gastrointestinal
Musculoskeletal†
Skin
PGF
Diabetes
Malignancy
B
Total SDI＊,♯,†
0.5 1 1.5 2 2.5
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???? ?　 Comparison of total SDI score and SDI score by organ.  
Open circle,  X-mark,  and closed circle show the mean SDI score 
of the past-,  middle-,  and recent-onset groups,  respectively.  Bars 
show the standard error.  Comparisons between the past-,  middle-,  
and recent-onset groups were performed using the Mann‒Whitney U 
test or Fisherʼs exact probability test.  Statistical significance was 
determined by using the Bonferroni correction (p<0.05/3): ＊Past-
onset vs middle-onset group; ＃Middle-onset vs recent-onset group;
†Past-onset vs recent-onset group.
SDI,  the Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology Damage Index;  PGF,  premature gonadal 
failure.
about 1 point per 10 years [12],  the observation period 
of the recent-onset group might have been too short to 
evaluate factors related to the SDI score.
There are several limitations to this study.  First,  we 
could not assess disease relapses in the present study.  
Relapses may have affected the chronic damage,  partic-
ularly in the group with long disease duration.  
However,  patients in the past-onset group were fre-
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????? ?　 Linear regression analysis of total SDI: Past-onset group
Univariate Multivariate
Coefficient 95% CI p-value Coefficient 95% CI p-value
Sex 0.30 -0.55,  1.15 0.48
Age of disease onset 0.03 -0.003,  0.06 0.08
Disease duration 0.05 -0.01,  0.12 0.11
Weight -0.004 -0.05,  0.04 0.86
BMI 0.04 -0.07,  0.15 0.50
SLEDAI 0.05 -0.04,  0.15 0.26
Dosage of PSL 0.09 -0.03,  0.21 0.15
GC monotherapy 0.69 0.28,  1.11 0.001 0.63 0.21,  1.05 0.004
WBC count 0.0001 -0.00005,  0.0003 0.13
Lymphocyte count 0.01 -0.03,  0.06 0.60
Plt, 0.008 -0.05,  0.06 0.78
CRP 0.85 0.46,  1.24 <0.0001 0.67 0.27,  1.07 0.002
C3 0.02 -0.004,  0.04 0.11
C4 0.08 0.02,  0.13 0.008 0.002 -0.03,  0.08 0.40
CH50 0.03 -0.02,  0.08 0.24
Anti-ds-DNA antibody 0.007 -0.007,  0.02 0.32
HbA1c 0.71 -0.01,  1.43 0.05
SDI,  Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; CI,  confidence interval; BMI,  
body mass index; SLEDAI,  Systemic Lupus Erythematosus Disease Activity Index; PSL,  prednisolone; GC,  glucocorticoid; WBC,  white 
blood cell; Plt,  platelet; CRP,  C-reactive protein; ds-DNA,  double strand-deoxyribonucleic acid.
????? ?　 Linear regression analysis of total SDI: Middle-onset group
Univariate Multivariate
Coefficient 95% CI p-value Coefficient 95% CI p-value
Sex 0.67 0.07,  1.27 0.03 0.47 -0.17,  1.11 0.15
Age of disease onset 0.05 0.03,  0.07 <0.0001 0.05 0.02,  0.08 0.002
Disease duration 0.03 -0.11,  0.18 0.66
Weight 0.03 -0.004,  0.06 0.09
BMI 0.08 -0.03,  0.18 0.14
SLEDAI 0.09 0.03,  0.15 0.004 0.09 0.03,  0.12 0.006
Dosage of PSL -0.02 -0.09,  0.06 0.62
GC monotherapy 0.04 -0.38,  0.47 0.84
WBC count 8.46e-5 -0.0001,  0.0002 0.37
Lymphocyte count 0.007 -0.03,  0.04 0.71
Plt -0.010 -0.06,  0.04 0.68
CRP 0.78 -0.02,  1.57 0.06
C3 0.02 0.007,  0.04 0.006
C4 0.09 0.04,  0.14 0.0005
CH50 0.04 -0.001,  0.08 0.06
Anti-ds-DNA antibody -0.005 -0.01,  0.004 0.25
HbA1c 1.02 0.08,  1.97 0.03 0.01 -0.95,  0.98 0.98
SDI,  Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; CI,  confidence interval; BMI,  
body mass index; SLEDAI,  Systemic Lupus Erythematosus Disease Activity Index; PSL,  prednisolone; GC,  glucocorticoid; WBC,  white 
blood cell; Plt,  platelet; CRP,  C-reactive protein; ds-DNA,  double strand-deoxyribonucleic acid.
quently treated with GC monotherapy and lower GC 
dosage,  and therefore additional immunosuppressants 
might not be needed due to the less frequent relapses.  
Second,  the beneficial effects of HCQ could not be con-
sidered,  because HCQ was not available for SLE treat-
ment in Japan until 2015.  However,  this situation could 
make it possible to elucidate the risk factors for chronic 
damage more clearly.
In conclusion,  the present study showed that reduc-
ing the accumulation of chronic damage in SLE patients 
would be possible,  depending on the concomitant use 
of immunosuppressants and rapid and tight control of 
disease activity.
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